China Research of IDEgAsp Treatment in Real-world Clinical practicE (CREATE)

Inclusion Criteria

• •1. Signed consent obtained before any study-related activities (study-related activities are any procedure related to recording of data according to the protocol).
• •2. The decision to initiate treatment with commercially available Ryzodeg® has been made by the patient/Legally Acceptable Representative (LAR) and the treating physician based on the approved Ryzodeg® label in China and independently from the decision to include the patient in this study.
• •3. Male or female, age above or equal to 18 years at the time of signing informed consent.
• •4. Diagnosed with T2DM and treated with any anti-hyperglycaemic medication(s) other than Ryzodeg® for at least 20 weeks prior to Treatment Initiation Visit (Visit 1).
• •5. Available and documented Glycosylated haemoglobin (HbA1c) value below or equal to 12 weeks prior to Informed Consent and Treatment Initiation Visit (Visit 1).